C ardiac hypertrophy is a compensatory mechanism of the heart, as it is critical for the maintenance of normal contractile function in response to chronic increases in hemodynamic load. Hypertrophy can initially be viewed as a salutary response; ultimately, however, it often heralds decompensation and transition to heart failure. 1 Whereas the signal transduction pathways promoting cardiomyocyte hypertrophy have been characterized in great detail, there is insufficient knowledge regarding signaling pathways that oppose cardiomyocyte hypertrophy. It has been reported, however, that NO, through activation of soluble guanylyl cyclase and cGMP formation, attenuates the hypertrophic response to growth factor stimulation in cardiomyocytes. 2, 3 In agreement with these in vitro studies, treatment of spontaneously hypertensive rats with the NO precursor L-arginine increases cardiac NO X and cGMP content and inhibits cardiac hypertrophy independent of blood pressure. 4 In addition to its antihypertrophic effect, NO has been shown to promote apoptosis in cardiomyocytes in a dose-dependent manner. 5, 6 However, the role of cGMP in the proapoptotic effects of NO is controversial. In fact, cGMP analogs have been reported both to induce 5 and not to induce 6 apoptosis in cardiomyocytes, and it has been proposed that NO promotes cardiomyocyte apoptosis by cGMP-independent mechanisms through formation of peroxynitrite. 6 -8 Downstream targets for cGMP-mediated antihypertrophic and, possibly, proapoptotic effects in cardiomyocytes have not been elucidated. In general, cGMP effectors include cGMP-regulated phosphodiesterases, cGMP-regulated ion channels, and cGMP-dependent protein kinases (PKGs). 9 Two PKG genes have been identified in mammalian cells, encoding for PKG type I (including ␣-and ␤-splice variants) and PKG type II. 9 In cardiomyocytes, PKG I has been suggested to mediate negative inotropic effects of NO/cGMP, possibly through regulation of the L-type Ca 2ϩ channel and troponin I, thereby reducing Ca 2ϩ -influx and myofilament Ca 2ϩ sensitivity. 10 -13 However, a role for PKG I in controlling cardiomyocyte hypertrophy and/or apoptosis has not been reported. In this study, we demonstrate for the first time that PKG I mediates antihypertrophic but not proapoptotic effects of NO in cardiomyocytes.
Methods

Materials
8-Para-chlorophenylthio-cGMP (8-pCPT-cGMP) and Sp-5,6-DClcBIMPS (cBIMPS) were purchased from Biolog. S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and phenylephrine (PE) were obtained from Calbiochem and Sigma, respectively.
Cardiomyocyte Culture
Ventricular cardiomyocytes were isolated from 1-to 3-day-old Sprague-Dawley rats by Percoll gradient. 14 Cells were plated overnight in Dulbecco's modified Eagle's medium (DMEM)/medium-199 (4:1) supplemented with 10% horse serum, 5% fetal calf serum, glutamine, and antibiotics. The next morning, cardiomyocytes were switched to DMEM/medium-199 supplemented only with glutamine and antibiotics (maintenance medium).
Immunofluorescence and Immunoblotting
Cardiomyocytes were immunostained for troponin T and PKG I according to a previously published procedure, 14 with a monoclonal antibody directed against troponin T (Sigma) and a polyclonal antibody raised against recombinant human PKG I. 15 Expression of PKG I and PKG II and phosphorylation of vasodilator-stimulated phosphoprotein (VASP) were analyzed by immunoblotting. 15, 16 
Adenoviral Infection of Cardiomyocytes
A replication-deficient adenovirus containing the cDNA of human PKG I␤ (Ad.PKG I␤) 17 was used to overexpress PKG I in cardiomyocytes. As a control, we used a replication-deficient adenovirus encoding a catalytically inactive form of PKG I␤ (Ad.PKG I␤-K405A), generated by replacing Lys 405 in the ATP-binding site of PKG I␤ by Ala. 18 After overnight plating, cardiomyocytes were switched to maintenance medium and infected for 2 hours with recombinant adenoviruses. After removal of the virus suspension, cardiomyocytes were incubated in maintenance medium supplemented with 5% fetal calf serum to allow for expression of wild-type or mutated PKG I␤. After 24 hours, cardiomyocytes were switched back to maintenance medium and stimulated with various agents. Cardiomyocytes were routinely infected with 1ϫ10 4 viral particles/ cell. At this concentration, Ad.PKG I␤ augmented cGMP-stimulated PKG activity (determined by in vitro kinase assay 19 
Assessment of Cardiomyocyte Hypertrophy and Survival
Cardiomyocyte surface area was determined by planimetry with phase contrast microscopy and a digital image analyzer (Leica Q500 MC). [ 3 H]leucine incorporation was measured as an index of total protein synthesis. 20 Prepro ANP mRNA/18S expression was assessed by Northern blot hybridization. 14 To determine cell viability, cells were analyzed by phase contrast microscopy immediately before the 24-hour stimulation period. For each condition, a random field (Ϸ200 cells) was chosen and marked on the outside of the well. Cells attached to the gelatin matrix were counted. After 24 hours, the same field was located, and cell survival was determined by trypan blue exclusion. The formation of histone-associated DNA fragments was quantified by cell death detection ELISA PLUS (Roche). 21 As a positive control for apoptosis, cardiomyocytes were subjected to serum and glucose deprivation. 22 
Statistical Analysis
Data are presented as meanϮSEM. Results are from Ն3 (where shown) experiments. Differences between groups were analyzed by 1-way ANOVA followed by Student's t test with Bonferroni correction. A 2-tailed value of PϽ0.05 was considered to indicate statistical significance.
Results
Cardiomyocytes Express Functionally Active Endogenous PKG I
PKG type I was readily detectable in neonatal cardiomyocytes by immunofluorescence ( Figure 1 , A and B) and by immunoblotting ( Figure 1C ), whereas PKG type II was undetectable ( Figure 1D ). PKG I expression was most abundant at sites of cell-cell contact (arrows in panel B). Expression levels of PKG I in ventricular cardiomyocytes and in 1-day-old rat heart ventricles were comparable, indicating that myocytes significantly contribute to the expression of PKG I in neonatal heart ( Figure 1C ). To demonstrate functional activity of endogenous PKG I in cardiomyocytes, we analyzed the phosphorylation status of VASP, a cytoskeletonassociated protein, and established PKG substrate in many 
Downregulation of Endogenous PKG I Expression and Function in Response to Long-Term Activation
As shown in Figure 3 
Gene Transfer of PKG I␤ Does Not Promote Cardiomyocyte Apoptosis
Because NO donors and, in some studies, cGMP analogs have been reported to induce apoptosis in neonatal cardiomyocytes, we determined whether PKG I affects cardiomyocyte survival. Exposure of noninfected cardiomyocytes to 250 mol/L SNAP or 500 mol/L 8-pCPT-cGMP, that is, concentrations that partially suppressed ␣ 1 -adrenergic hyper- trophy, did not reduce cell viability and did not promote DNA fragmentation, a marker of apoptotic cell death ( Figure 5A and 5B, left panels). By contrast, a higher concentration of SNAP (1000 mol/L) resulted in a significant decrease in cell viability accompanied by the accumulation of histoneassociated DNA fragments ( Figure 5A and 5B, left panels).
Comparable results were obtained in cardiomyocytes infected with adenoviruses carrying no foreign cDNA insert (data not shown) or expressing catalytically inactive PKG I␤-K405A ( Figure 5A and 5B, center panels) or wild-type PKG I␤ ( Figure 5A and 5B, right panels). SNAP and 8-pCPT-cGMP exerted similar effects on cardiomyocyte survival in the presence or absence of phenylephrine ( Figure 5A and 5B).
Discussion
This study provides the first evidence that cGMP-dependent protein kinase type I promotes antihypertrophic but not proapoptotic effects of NO/cGMP in cardiomyocytes. Furthermore, our results indicate that adenoviral gene transfer of PKG I is a powerful molecular approach to selectively potentiate the antihypertrophic effects of NO/cGMP without increasing the susceptibility to apoptotic cell death. Consistent with previous reports that indicated that negative inotropic effects of NO/cGMP in mammalian cardiomyocytes are mediated through stimulation of PKG, 10 -13 our data show that neonatal rat ventricular cardiomyocytes express endogenous PKG I. This endogenous PKG I is a downstream target for NO/cGMP in cardiomyocytes, as demonstrated by the site-specific phosphorylation of VASP, a wellcharacterized PKG substrate, 16 in response to stimulation with the NO donor SNAP or the PKG-selective cGMP analog 8-pCPT-cGMP. 23 Treatment with SNAP or direct activation of endogenous PKG I with 8-pCPT-cGMP attenuated the hypertrophic response to ␣ 1 -adrenergic stimulation. Inhibitory effects of NO and endogenous PKG I on ␣ 1 -adrenergic hypertrophy were rather weak, however.
Similar to observations in vascular smooth muscle cells, 24 prolonged activation resulted in downregulation of endogenous PKG I expression and function in cardiomyocytes. Therefore, we explored whether gene transfer of PKG I might enhance the antihypertrophic effects of NO/cGMP. Indeed, after adenoviral overexpression of PKG I␤, SNAP and 8-pCPT-cGMP completely suppressed ␣ 1 -adrenergic hypertrophy. Importantly, gene transfer of catalytically inactive PKG I␤-K405A, carrying a point mutation in the ATPbinding site, 18 did not augment the antihypertrophic effects of SNAP and 8-pCPT-cGMP. Therefore, nonspecific effects possibly related to the overexpression of a foreign protein are extremely unlikely. While our experiments were in progress, it was reported that rabbit cardiomyocytes predominantly express the ␣-splice variant of PKG I. 25 PKG I␣ and PKG I␤ have been shown to bind to and phosphorylate common target proteins in heart 13 but also distinct target proteins in other tissues. 26 Using a replication-deficient adenovirus expressing human PKG I␣, we found that the inhibitory effects of PKG I␣ overexpression on ␣ 1 -adrenergic hypertrophy are virtually indistinguishable from the effects observed after gene transfer of PKG I␤ (data not shown), indicating that phosphorylation targets critical for antihypertrophic effects in heart are shared by PKG I␣ and PKG I␤.
Potential targets for PKG I in cardiomyocytes include Ca 2ϩ -dependent signaling pathways, RhoA, and, as shown here, VASP. The function of VASP in cardiomyocytes is still poorly understood. Localization of VASP at intercalated discs in cardiomyocytes 27 suggests that VASP may be involved in PKG I regulation of electrical coupling. 28 Moreover, because VASP has been shown to control cytoskeletal actin filament assembly in other cell types, 29 the L-type Ca 2ϩ channel and the 1,4,5-trisphosphatereceptor. 10, 32 PKG I inhibition of the L-type Ca 2ϩ current, for example, may mediate negative inotropic effects of NO/ cGMP in cardiomyocytes. Importantly, Ca 2ϩ influx through the L-type Ca 2ϩ -channel has also been implicated in the regulation of cardiomyocyte hypertrophy. 33 Therefore, antihypertrophic effects of PKG I may be mediated in part through inhibition of Ca 2ϩ -dependent signaling pathways in cardiomyocytes. The low-molecular-weight GTPase RhoA, which is required for ␣ 1 -adrenoreceptor signaling in cardiomyocytes, 34 may represent an additional PKG I target. PKG I has recently been shown to phosphorylate RhoA and inhibit its biological activity in vascular smooth muscle cells, 35 suggesting that inhibition of RhoA may contribute to the antihypertrophic effects of PKG I. Clearly, further studies will be required to identify which of its many molecular targets PKG I uses to inhibit cardiomyocyte hypertrophy.
Importantly, the concentration of SNAP that partially suppressed ␣ 1 -adrenergic hypertrophy in noninfected cardiomyocytes did not reduce cell viability. Only exposure of cardiomyocytes to a higher concentration of SNAP induced cell death and DNA fragmentation. Direct activation of endogenous or overexpressed PKG I by 8-pCPT-cGMP did not promote apoptotic cell death. Furthermore, overexpression of PKG I␤ did not enhance the susceptibility of cardiomyocytes to the proapoptotic effects of SNAP. Taken together, our data argue against a role for PKG I in promoting apoptosis in neonatal cardiomyocytes and support the concept that proapoptotic effects of NO in neonatal cardiomyocytes are mediated by cGMP-independent 6 -8 rather than cGMPdependent 5 mechanisms. This conclusion is further supported by immunoblotting experiments (data not shown) demonstrating that antihypertrophic concentrations of SNAP or 8-pCPT-cGMP do not promote cleavage of the caspase-3 substrate PKC ␦ (method according to Reference 22) in noninfected or PKG I␤ overexpressing cardiomyocytes, whereas the positive control of serum and glucose deprivation always caused PKC ␦ cleavage. Although our data indicate that PKG I does not promote apoptosis in cardiomyocytes, we cannot rule out small effects on cardiomyocyte survival that are below the detection limit of our assays.
In summary, antihypertrophic effects of PKG I are not associated with a decrease in cardiomyocyte survival, and gene transfer of PKG I may therefore represent a valuable strategy to selectively inhibit cardiomyocyte hypertrophy. However, our data were derived from neonatal cardiomyocytes stimulated with phenylephrine in vitro, which is a limited model of cardiac hypertrophy. Therefore, in the future, studies of the signaling pathways mediating antihypertrophic effects of NO/cGMP need to be extended to investigations with adult cardiomyocytes and pressureoverload hypertrophy in vivo. In this regard, a number of recent studies suggest that NO/cGMP and ANP/cGMP signaling pathways do exert antihypertrophic effects in vivo, independent of blood pressure. 4, 36, 37 To characterize downstream targets mediating the antihypertrophic effects of cGMP in vivo and to further explore the role of PKG I in the adult and in vivo situation, we are currently generating transgenic mice with cardiac-specific overexpression of PKG I. For each condition, cell numbers at beginning of 24-hour incubation period were defined as 100%. B, Quantification of histone-associated DNA fragments by ELISA (nϭ4 experiments). **PϽ0.01, ***PϽ0.001 vs control. #PϽ0.05, ##PϽ0.01, ###PϽ0.001 vs PE. For positive controls, cells were subjected to 24-hour serum and glucose deprivation, resulting in a significant reduction of cell viability (15Ϯ3%) associated with release of histone-associated DNA fragments (0.53Ϯ0.06 OD).
